Physician profile
Wanjun S Bae
NPI 1457433906
$15,866.47
in general payments reported to CMS, 2019-2025
42 companies · $4,448 in 2025
The $4,448 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $342 · 2021: $127 · 2022: $2,731 · 2023: $3,167 · 2024: $3,925 · 2025: $4,448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $94.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,445.08 |
| Education | $94.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,450.10 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,515.32 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,457.23 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,239.60 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $794.67 | 2019-2025 | |
| Genzyme Corporation | $627.39 | 2022-2025 | |
| Celgene Corporation | $545.49 | 2022-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $481.53 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $353.79 | 2024-2025 | Ibsrela |
| Celltrion USA INC. | $275.35 | 2024-2025 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $268.79 | 2024-2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $253.86 | 2021-2022 | |
| Madrigal Pharmaceuticals | $247.89 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $243.16 | 2022-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $229.26 | 2019-2025 | Ocaliva |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $196.97 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $176.91 | 2019-2025 | |
| Braintree Laboratories, INC. | $167.76 | 2022-2025 | Suflave, Sutab |
| Vivus LLC | $145.48 | 2019-2025 | Qsymia, Pancreaze |
| Covidien LP | $142.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $140.96 | 2022-2024 | Rebyota, Clenpiq |
| Janssen Scientific Affairs, LLC | $124.48 | 2020 | |
| Daiichi Sankyo INC. | $98.89 | 2019-2022 | |
| Allergan, INC. | $66.56 | 2019-2020 | |
| Medtronic, INC. | $65.88 | 2022-2024 | Nexpowder, Gi Genius |
| Fresenius Kabi USA, LLC | $60.10 | 2023 | Idacio |
| Redhill Biopharma INC. | $56.66 | 2022-2023 | Talicia |
| Boston Scientific Corporation | $53.91 | 2022-2024 | Exalt Model D |
| Exact Sciences Corporation | $49.44 | 2023-2025 | Cologuard Collection Kit |
| Alfasigma USA, INC. | $43.91 | 2022 | |
| Sandoz INC. | $36.85 | 2025 | Hyrimoz |
| Shionogi INC | $31.60 | 2019 | |
| Merck Sharp & Dohme LLC | $31.11 | 2019 | |
| Ironwood Pharmaceuticals, INC | $30.83 | 2022 | |
| Astellas Pharma US INC | $27.97 | 2025 | Vyloy |
| Biocon Biologics INC | $27.34 | 2025 | Hulio |
| Ambu INC. | $26.46 | 2020 | |
| Alcresta Therapeutics, INC. | $22.04 | 2024 | Relizorb |
| Axonics, INC. | $21.42 | 2022 | |
| W. L. Gore & Associates, INC. | $19.07 | 2020 | |
| Olympus America INC. | $15.54 | 2021 | |
| Intra-Sana Laboratories | $2.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanjun Bae listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.